Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing next week to defend the ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the fo ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

New York Gov. Kathy Hochul announced she would not remove New York City Mayor Eric Adams from office over federal corruption ...

An outbreak of measles is wreaking havoc in the South Plains region of Texas, where nearly 60 children have been confirmed to ...